X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
0
Europe
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
Details:
One cycle of IMX-110 (curcumin) produced 75% survival vs. 0% survival for Trabectedin (sold as YONDELIS ® by Janssen, a Johnson & Johnson Company, a U.S. FDA approved drug).
Lead Product(s): Curcumin,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: IMX-110
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Johnson & Johnson
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 20, 2022
Details:
Through this partnership, and through HempStreet’s extensive distribution reach and key institutional partnerships, Indian patients will now have access to these medicines, starting with CimetrA (Artemisinin), which had an immediate need.
Lead Product(s): Artemisinin,Curcumin,Boswellia Serrata
Therapeutic Area: Infections and Infectious Diseases Product Name: CimetrA
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: MGC Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership May 07, 2022
Details:
Slendacor, a patented combination of three extracts of turmeric, drumstick leaves, and curry leaves showed up to a 15.2% increase in resting energy expenditure at Day 7, reshape fat metabolism & improve cardiometabolic health while helping people lose weight.
Lead Product(s): Curcumin,Moringa Oleifera,Murraya Koenigii
Therapeutic Area: Nutrition and Weight Loss Product Name: Slendacor
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 02, 2022
Details:
The study includes 150 adult patients with a confirmed SARS-CoV-2 infection, at least 4 weeks of long-COVID symptoms, and a Post Covid Functional Score (PCFS) between one and four. ArtemiC Support is administered orally, in a dosage of 5 drops three times daily for 6 weeks.
Lead Product(s): Artemisinin,Curcumin,Frankincense
Therapeutic Area: Infections and Infectious Diseases Product Name: ArtemiC
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: MGC Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2021
Details:
MGC Pharma has secured this import license from CDSCO for CimetrA to enable it to submit final samples of CimetrA for testing and analysis. CimetrA is a nanoparticle micellar formulation based on a synergetic composition consisting of Curcumin and Boswellia.
Lead Product(s): Curcumin,Boswellia Serrata
Therapeutic Area: Infections and Infectious Diseases Product Name: CimetrA
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 02, 2021
Details:
The Malta facility will create a European manufacturing hub for ArtemiCTM with the ability to scale production to meet expected growing demand following positive clinical trial results.
Lead Product(s): Artemisinin,Curcumin,Boswellia Serrata
Therapeutic Area: Infections and Infectious Diseases Product Name: ArtemiC
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Malta Enerprises
Deal Size: $3.7 million Upfront Cash: $3.7 million
Deal Type: Funding December 22, 2020
Details:
Interim Results reported to date demonstrate ArtemiCTM has met all primary end points for safety and efficacy, and FDA primary endpoint of sustained clinical recovery of COVID-19 patients.
Lead Product(s): Artemisinin,Curcumin,Frankincense
Therapeutic Area: Infections and Infectious Diseases Product Name: ArtemiC
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2020
Details:
The trial is assessing the safety and efficacy of the natural anti-inflammatory formulation ArtemiCTM, a natural supplement formula based on Artemisinin and Curcumin (along with supporting ingredients Vitamin C and Boswellia serrata) on COVID-19 Patients.
Lead Product(s): Artemisinin,Curcumin,Frankincense
Therapeutic Area: Infections and Infectious Diseases Product Name: ArtemiC
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2020
Details:
Lipocurc has advantage of not only safely suppressing interleukin-6 by 83%, it also profoundly suppresses TNF-alpha by 77% and IL-1 beta by 85% as well as suppressing RANTES, IL-8, MCP-1& MIP-alpha.
Lead Product(s): Curcumin
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 17, 2020
Details:
The expansion of the study to the US builds upon Immix' results from Australia, wherein 6 cohorts were dosed with no treatment-related serious adverse events observed.
Lead Product(s): Curcumin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 04, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
